:: 가톨릭대학교 백혈병 연구소 ::
Num Title Journal name Journal date
10

BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia 

Korean J Intern Med 2017 Jan;32(1):125-136. doi: 10.3904/kjim.2015.187. Epub 2016 Jun 22.
9

Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. 

Leukemia 2017 Jul;31(7):1532-1539. doi: 10.1038/leu.2017.72. Epub 2017 Feb 24.
8

Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. 

Clinical Cancer Research 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.
7

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. 

LEUKEMIA & LYMPHOMA 2016 Aug;57(8):1856-64. doi: 10.3109/10428194.2015.1113278. Epub 2015 Dec 15.
6

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. 

HAEMATOLOGICA 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17.
5

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. 

LEUKEMIA & LYMPHOMA 2015 Jun 12:1-7. [Epub ahead of print]
4

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. 

CANCER RESEARCH AND TREATMENT 2015 Oct;47(4):937-42. doi: 10.4143/crt.2013.155. Epub 2014 Nov 17.
3

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. 

LEUKEMIA & LYMPHOMA 2015 Jun 12:1-7. [Epub ahead of print]
2

Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. 

LEUKEMIA RESEARCH 2015 Apr;39(4):411-8. doi: 10.1016/j.leukres.2015.01.011. Epub 2015 Jan 29.
1

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors". 

HAEMATOLOGICA 2015 Mar;100(3):e120-1. doi: 10.3324/haematol.2014.123232.
    이전페이지 1 다음페이지
비밀번호 입력
비밀번호
확인
비밀번호 입력
비밀번호
확인